Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Catalysis SL clinical trials
The registry lists 53 studies whose lead sponsor is Catalysis SL. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 17, 2025.
Keep track of what changes. Save the Catalysis SL studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Catalysis SL.
- Catalysis SL53 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 53. Browse all 53 →
- Efficacy of Carminal in Helicobacter Pylori GastritisRecruitingNCT07179237Phase 2
- Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid TumoursNot yet recruitingNCT06363201Not applicable
- Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial LesionsRecruitingNCT03549273Phase 2
- Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)RecruitingNCT05916911Phase 4
- Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine AssessmentCompletedNCT06496087Not applicable
- Evaluation of Treatment With Viusid in Post-COVID-19 SyndromeCompletedNCT06437210Not applicable
- Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in ChildrenCompletedNCT06361992Phase 3
- Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric JunctionCompletedNCT03549494Phase 2
- Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal AdenocarcinomaCompletedNCT03559543Phase 2
- The Effectiveness of Spermotrend Food Supplement in the Treatment of Male InfertilityCompletedNCT05222841Phase 2/3
- Evaluation of Ocoxin-Viusid® in Advanced Pancreatic AdenocarcinomaCompletedNCT03717298Phase 2
- Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial CancerCompletedNCT03562897Phase 2
- Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + AsbripCompletedNCT04980534Not applicable
- Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19CompletedNCT04701502Phase 2
- Evaluation of Obex® in Overweight and ObesityCompletedNCT03541005Phase 3
- Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19CompletedNCT04407182Phase 2
- Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral TractCompletedNCT04695951Phase 2
- Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.CompletedNCT03540407Phase 2
- Oncoxin® and Quality of Life in Cancer PatientsCompletedNCT03550482Phase 4
- Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus EsophagealCompletedNCT03584308Phase 2
- Evaluation of Oncoxin-Viusid® in Prostate CancerCompletedNCT03543670Phase 2
- Alzer® and Diamel® to Prevent Severe Diabetes Macular EdemaCompletedNCT03533478Phase 2
- Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.CompletedNCT03577535Phase 2
- Evaluation of DIAMEL® Combined With Insulin in Diabetic Foot UlcerCompletedNCT03583593Phase 2
- Evaluation of Ocoxin®-Viusid® in Breast CancerCompletedNCT03576521Phase 2
- Evaluation of Oncoxin-Viusid® in Head and Neck CancerCompletedNCT03541772Phase 2
- Evaluation of Oncoxin-Viusid® in Cutaneous MelanomaCompletedNCT03541148Phase 2
- Effects of Obex in Overweight and Obese PatientsCompletedNCT02145442Phase 2/3
- Obex, a Nutritional Supplement, in Overweight and Obese Spanish WomenCompletedNCT01934036Phase 2/3
- Glizigen-Viudid-External Anogenital Warts in Children and AdolescentsCompletedNCT01111344Phase 3
- Renalof in the Treatment of Elderly Patients With GallstonesCompletedNCT01099319Phase 3
- Diamel in the Treatment of Polycystic Ovary SyndromeCompletedNCT01051024Phase 3
- Melanil in the Treatment of MelasmaCompletedNCT01001624Phase 3
- Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic DiseaseCompletedNCT00967681Phase 3
- Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis CCompletedNCT00778843Phase 3
- Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's DiseaseCompletedNCT01016470Phase 3
- Efficacy and Safety of Diamel in Patients With Nonalcoholic SteatohepatitisCompletedNCT00820651Phase 3
- Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid ArthritisCompletedNCT00969527Phase 3
- Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin TherapyCompletedNCT00994266Phase 3
- Deprexil in Subjects With Signs and Symptoms of DepressionCompletedNCT01043367Phase 3
- Spermotrend in the Treatment of Male InfertilityCompletedNCT00975117Phase 3
- Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.CompletedNCT00502086Phase 3
- Cicatrix Cream in Post Surgical Scars and Epidermic BurnCompletedNCT01018589Phase 2
- CICATRIX in the Treatment of Recent Post-surgical ScarsCompletedNCT00991367Phase 3
- Cicatrix Cream in Cutaneous GrovesCompletedNCT01018212Phase 2
- CICATRIX in the Treatment of Hypertrophic Scars and Keloids ScarsCompletedNCT00993005Phase 3
- Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis TreatmentSuspendedNCT00978224Phase 3
- Retorna Facial Cream in the Treatment of Facial WrinklesCompletedNCT00978887Phase 3
- Viusid in Adults With Acute Fever of Viral EtiologyCompletedNCT01008007Phase 2
- Diamel in the Treatment of Metabolic SyndromeCompletedNCT01025115Phase 3